Changing risk factors in childhood acute lymphoblastic leukemia: experience from Kujawsko-Pomorski region 1976–2018

Joanna Stankiewicz,Ewa Demidowicz,Agnieszka Jatczak-Gaca,Natalia Bartoszewicz,Andrzej Kołtan,Sylwia Kołtan, K Czyżewski,Monika Richert-Przygońska,Robert Dębski,Monika Pogorzała,Barbara Tejza, Piotr Księżniakiewicz, Joanna Cisek,Marlena Ewertowska,Agata Marjańska, Anna Dąbrowska,Anna Urbańczyk,Elżbieta Grześk, Kamila Jaremek, Eugenia Winogrodzka, Dominika Kołuda,Monika Łęcka, Monika Adamkiewicz, Sandra Wałach, Oliwia Grochowska,Sonia Tarasenko, Marta Mazalon,Magdalena Dziedzic,Małgorzata Kubicka,Beata Kuryło-Rafińska, Ewa Dembna, Agnieszka Majk,Mariusz Wysocki,Jan Styczyński

Acta haematologica Polonica(2023)

引用 0|浏览6
暂无评分
摘要
Introduction: Acute lymphoblastic leukemia (ALL) is the most common malignancy in children. Risk factors in childhood ALL have changed during recent decades, mostly due to treatment personalization. The aim of this study was to analyze therapy results and prognostic factors in childhood ALL in the Kujawsko-Pomorski region of Poland between 1976 and 2018. Material and methods: Data from 495 patients (0–18 years old) diagnosed with ALL from the Kujawsko-Pomorski region between 1976 and 2018 was analyzed. Prognostic factors were analyzed separately in specific therapeutic groups, which were defined by several therapy protocols. Results: Prognostic factors have changed over the course of consecutive therapeutic periods. Between 1976 and 1988 (the first and second therapeutic protocols), central nervous system involvement was the most important risk factor. During the third therapeutic period, an unsatisfactory treatment response on days 8 and 14 was related to a poor outcome. In 1995–2002, the risk factors were hepatomegaly, splenomegaly, lymph nodes involvement, and unsatisfactory therapy response on days 15 and 33. Between 2002 and 2011, immunophenotype other than ‘common’ and hemoglobin level at diagnosis were the risk factors, and a lack of BCR-ABL aberration was related to better therapy results. During the final analyzed period (2011–2018), failure to achieve remission on day 33 was a risk factor, and patients classified as non-high risk group and those aged <6 years had better outcomes. Conclusions: The changing profile of risk factors in ALL has reflected progress in ALL therapy, with the gradual elimination of factors related to poor outcomes, mostly due to modifications in treatment and the development of diagnostic methods as well as therapy monitoring.
更多
查看译文
关键词
acute lymphoblastic leukemia,lymphoblastic leukemia,childhood acute,risk factors,kujawsko-pomorski
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要